… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNAediting technology platform, today announced the Annual …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … candidates, and to advance our Axiomer ® and Trident ™ RNA-editing technology platforms.” Business Operations and … ® EONs are designed to recruit an endogenously expressed RNAediting system called ADAR, which can direct the change …
… on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Key program features and updates: ProQR to … Axiomer®: ProQR will introduce its novel, proprietary RNAediting platform technology. Art Levin, Ph.D., an …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … review of the Company’s clinical-stage programs and RNAediting technology platforms. A webcast replay of the …
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022
Phase 2/3 Sirius and Celeste clinical trials of ultevur
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … Annual Conference A presentation titled “Therapeutic RNAediting by Axiomer ® editing oligonucleotides” by Janne …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today announced that it has …
… two companies will work together to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis targets … collaboration are not disclosed. ProQR is developing its RNA platform technology in areas of ophthalmology, cystic … look forward to collaborating with ProQR and its exciting RNAediting technologies.” About ProQR ProQR Therapeutics is …